Deeply integrate "AI+BT+IT"! MGI Tech Co., Ltd. (688114.SH) will incorporate generative AI technology into life science tools.

Recently, AI+ medical concept stocks have performed strongly in the capital market, with several related medical stocks hitting new highs in stock prices in the past year, becoming the focus of the market. In addition to the boost from the domestic substitution benefits of global direct competitors such as Illumina being included in the "list" by the Ministry of Commerce, as well as the catalyst of the "AI+ medical" concept, MGI Tech Co., Ltd. (688114.SH) has demonstrated an exciting performance in stock price after the Spring Festival, with the company's stock price rising by approximately 53% as of February 20, and the market value increasing by over 10 billion RMB. Since February of this year, when MGI Tech Co., Ltd. announced that it would fully integrate AI technology into its existing laboratory automation business and upgrade it to an intelligent laboratory automation business, the company has been continuously making efforts in the AI+ medical field, integrating AI artificial intelligence technology into the field of life science tools. Gene sequencers are one of the most important high-end devices and underlying tools in the field of life sciences, and they are also the gateway and bottleneck for translating genetic codes into large-scale life data. On February 20th, MGI Tech Co., Ltd. officially released the new self-luminous semiconductor gene sequencer - DNBSEQ-E25 Flash (referred to as E25 Flash). Combining a series of AI tools, E25 Flash achieves double improvements in biochemical raw materials and base algorithms compared to the original E series sequencer models. It is reported that each sequencing cycle of E25 Flash Flash gene sequencer only takes 75 seconds, and SE50 sequencing can be completed within 2 hours. The sequencing speed of 2 hours also refreshes the fastest record of second-generation sequencers. This Flash gene sequencer can meet the extreme demands for Turn Around Time (TAT) of more applications. With the benefit of Flash sequencing solutions, E25 Flash is expected to play a leading role in public health, infectious disease diagnosis, and other fields. For example, a certain disease prevention and control center in China adopted MGI Tech Co., Ltd.'s monkeypox whole genome target library construction scheme combined with the E25 Flash Flash sequencing scheme, and completed the correct typing of monkeypox cases in only 9 hours, obtaining the assembly of the complete virus genome in just 3.3 hours (SE100 read length). Dr. Yang Meng, Vice President of MGI Tech Co., Ltd. said, "The integration and innovation of biotechnology and information technology is an inevitable trend in the industry. The self-luminous semiconductor sequencing route is actually empowering our BT field product development using the crown jewel semiconductor technology in the industrial field. We hope to make this technology more open and open-source, and cooperate with partners and downstream manufacturers. Only through open cooperation, reusing supply chain and algorithm capabilities, can we break through technological barriers and truly serve global public health with genetic testing, achieving sequencing equality." The emergence of generative AI has brought great development opportunities and potential to the life sciences field. From precision medicine to medical innovation, from reducing high medical costs to improving intelligent decision-making efficiency, generative AI is reshaping the entire new value chain of the life sciences industry. According to Data Bridge Market Research's analysis, the global medical generative AI market is expected to reach 1.8 billion USD in 2023, and is expected to reach 17.2 billion USD by 2031, with a compound annual growth rate of 32.60%, showing immense application potential. This also makes the industry full of expectations for whether MGI Tech Co., Ltd. can be the "NVIDIA of the AI medical field." Since the release of the first domestic gene sequencer in 2015, MGI Tech Co., Ltd. has been deeply cultivating the field of genetic sequencing equipment for ten years, as a pioneer and leader in the genetic sequencing equipment industry, building the only global sequencing product matrix that gathers "excited light, self-luminous, non-luminous" three different sequencing technologies. In recent years, the company has gradually built a "more than sequencing, multidisciplinary platform integration" full-process one-stop solution for industry users. Intelligence and automation have also become the new pursuit of business development. According to a report released by IDC, with the rapid growth of the digital demand in China's life science industry, the market is expected to reach 55.98 billion RMB by 2028. So far, MGI Tech Co., Ltd. has served over 3000+ users worldwide. By deeply integrating "AI+ BT+ IT," the company is expected to help the industry truly achieve "full-scale research freedom," benefit a wider range of application scenarios, and with ample market potential.